China Digest: Drug developer Hope nets $56m; biotech firm Yikon raises $39m
Source: Laurynas Mereckas/Unsplash
May 6, 2021
Chinese innovative drug developer Hope Medicine has secured $56 million in a funding round led by investment firms Qiming Venture Partners and Grand Flight Investment, while biotech firm Yikon Genomics has raised 250 million yuan ($38.6 million).
Qiming, Grand Flight lead $56m round in drug maker Hope
Chinese drug developer Hope Medicine has secured $56 million in a Series B round of financing jointly led by investment firms Qiming Venture Partners and Grand Flight Investment, the startup announced on Thursday.
Health-focused investment platform HighLight Capital; Sinovation Ventures, a technology venture capital (VC) firm led by former Google China head Kai-Fu Lee; alongside growth equity firm Trustbridge Partners, which had backed Hope’s Series A round in 2019, all poured capital into the new round.
AYO partners with SA Innovation Summit for Scaling Africa series
By Philippa Larkin
Share
JOHANNESBURG - AYO TECHNOLOGY Solutions, in partnership with the SA Innovation Summit, said yesterday that it was proud to announce the first AYO Scaling Africa Series, an Africa-based initiative aimed at empowering technopreneurs.
The series would identify and support digital and tech businesses from South Africa, disrupting the ecosystem with novel ways to solve business and everyday needs for communities across South Africa and Africa, it said.
The “Africa Tech Venture Capital Report” shows that 347 African tech start-ups raised $1.4 billion (R20bn) last year.
“The AYO Scaling Africa Series will provide Series A funding-seekers with high-growth strategies and a sustainable competitive advantage, a chance to build capacity and grow. It aims to provide exposure, access to new markets, funding and scaling opportunities, and business support. Entries open on April 6 and are open t
streetAsia s premium subscription service Unlock your competitive advantage in a rapidly evolving landscape. Our packages come with exclusive access to archive content, data, discount on summit tickets & more. Be a part of our growing community now. SUBSCRIBE NOW
Singapore Reporter/s
In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digi
Share this article
Share this article
SHANGHAI, Dec. 22, 2020 /PRNewswire/ 111, Inc. ( 111 or the Company ) (NASDAQ: YI), a leading digital healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced the successful completion of new capital injection in its principal PRC subsidiary by a selected group of strategic and mission-driven investors.
On December 22, 2020, 1 Pharmacy Yaofang Technology (Shanghai) Co., Ltd. (previously known as Yao Fang Information Technology (Shanghai) Co., Ltd.) ( Yao Fang Shanghai ), the principal operating subsidiary of 111 in China, completed a new round of capital injection from strategic investors. According to the investment agreements, the investors invested in Yao Fang Shanghai an aggregate of RMB515 million (approximately US$78.75 million
How COVID-19 Is Affecting The Deep Tech Startup Ecosystem
COVID-19 has been the most profound shock to the national research enterprise since World War II. The repercussions are still shaking out, but lost research output due to temporary closures of most state economies has wreaked havoc on the pace of innovation and commercialization in the U.S. It is expected that the financial and economic effects of the pandemic on capital markets will be a catastrophic event for many early-stage companies, especially those that are bringing deep technologies to market. The first part of the Deep Dive Into Deep Tech Incubation webinar series will feature thought leaders from government, academia, startups, and the investment community to discuss how deep tech entrepreneurs can try to weather COVID-19 and make it out on the other side of this ongoing crisis stronger and better prepared.